Follow-up study for patients with primary hyperoxaluria type 1 on Lumasiran
Part of Genetic & congenital, Kidney & urinary clinical trials.
This study follows patients with primary hyperoxaluria type 1 who are being treated with Lumasiran. It aims to understand how well the treatment works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary hyperoxaluria type 1 (a rare disease that causes too much oxalate in your body).
- You have been treated with Lumasiran (a medication that lowers oxalate levels).
- You started treatment as part of a temporary authorization program or after it was approved for use.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Multiple Endocrine Neoplasia type 1 (MEN1) over time, including those with symptoms, certain isolated hormone gland problems, and people without symptoms who have the MEN1 gene change. It may help doctors learn how MEN1 starts and progresses so care can be better timed and personalized.
This trial tests a drug called Lumasiran to lower oxalate levels in patients on hemodialysis (a type of kidney dialysis). It may help reduce complications from high oxalate, which can damage organs.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
Hear when a new Patients With PH1 Treated With Lumasiran in France trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.